20th Annual Update in Pulmonary Hypertension

This live CME/CNE accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state of the art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines, research, and patient-centered outcomes.

Educational Outcome

This CE activity offers new and experienced healthcare providers state of the art education, recent data, case discussions, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes.

Objectives

After completing this activity, the participant should be better able to:

• Review new clinical trial designs and novel pathways being developed to improve treatment outcomes
• Examine clinical trial evidence on the safety and efficacy of current and emerging drug treatment options for PAH/PH
• Determine how and when to escalate therapy using pharmacological and non-pharmacological options based on an evidence-based management plan
• Learn how to organize interprofessional teams to best care for PH patients in need of surgical interventions
• Assess approaches to the management of complex and rare cases in PH based on actual case studies
• Describe characteristics of CTD-PAH patients and differences in PH between scleroderma, SLE, rheumatoid arthritis, and other connective tissue diseases
• Explain the algorithm for assessing PH-ILD as well as current treatment options and ongoing clinical trials

Target Audience

This activity is intended for physicians (pulmonologists, cardiologists, rheumatologists and general practitioners), fellows, residents, nurse practitioners, registered nurses and other healthcare practitioners engaged in the care of patients with pulmonary arterial hypertension.

Supporters/Exhibitors

The conference directors and planning committee would like to offer a special thank you to our 2023 exhibitors.

DIAMOND

Gossamer Bio
Johnson & Johnson
United Therapeutics Corporation

PLATINUM

Insmed
Liquidia
Merck & Co., Inc.

GOLD

Aerovate Therapeutics
Keros Therapeutics
Respira Therapeutics

BRONZE

Accredo Health
AstraZeneca
Bayer US Healthcare
Boehringer Ingelheim
CMP Pharma
CVS Specialty Pharmacy
Team PHenomenal Hope

Non-exhibiting support provided by TotalCME